NCT02758626View on ClinicalTrials.gov

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 27, 2021

Study Completion Date

February 27, 2021

Conditions

Epilepsy

Interventions

DRUG

ataluren

Powder formulation

DRUG

Placebo

Powder formulation

Trial Locations (1)

10016

New York University School of Medicine, New York

Sponsors

Collaborators (1)

PTC Therapeutics

All Listed Sponsors

collaborator

PTC Therapeutics

INDUSTRY

lead

NYU Langone Health

OTHER

NCT02758626 - Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome | Biotech Hunter | Biotech Hunter